Literature DB >> 30975907

Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.

Junko Yamaguchi1, Takahiro Fujino1, Reiko Isa1, Daichi Nishiyama1, Saeko Kuwahara-Ota1, Yuka Kawaji1, Taku Tsukamoto1, Yoshiaki Chinen1, Yuji Shimura1, Tsutomu Kobayashi1, Shigeo Horiike1, Kei Kohno2, Shigeo Nakamura2, Junya Kuroda3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30975907      PMCID： PMC6669167          DOI： 10.3324/haematol.2019.217141

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

Authors:  J W van Esser; B van der Holt; E Meijer; H G Niesters; R Trenschel; S F Thijsen; A M van Loon; F Frassoni; A Bacigalupo; U W Schaefer; A D Osterhaus; J W Gratama; B Löwenberg; L F Verdonck; J J Cornelissen
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

Review 2.  T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse.

Authors:  Andre E Nel
Journal:  J Allergy Clin Immunol       Date:  2002-05       Impact factor: 10.793

3.  EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate.

Authors:  Marcel W Bekkenk; Maarten H Vermeer; Chris J L M Meijer; Patty M Jansen; Jaap M Middeldorp; Servi J C Stevens; Rein Willemze
Journal:  Blood       Date:  2003-12-01       Impact factor: 22.113

4.  Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.

Authors:  Vassilia Garipidou; Sofia Vakalopoulou; Konstantinos Tziomalos
Journal:  Oncologist       Date:  2005 Jun-Jul

5.  Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Authors:  Lydia Roy; Joëlle Guilhot; Tillmann Krahnke; Agnès Guerci-Bresler; Brian J Druker; Richard A Larson; Steve O'Brien; Charlene So; Giorgio Massimini; François Guilhot
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

Review 6.  Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.

Authors:  Craig Kovitz; Hagop Kantarjian; Guillermo Garcia-Manero; Lynne V Abruzzo; Jorge Cortes
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

7.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440

8.  Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.

Authors:  Ruth Seggewiss; Karin Loré; Elisabeth Greiner; Magnus K Magnusson; David A Price; Daniel C Douek; Cynthia E Dunbar; Adrian Wiestner
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

9.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

Authors:  Deborah A Thomas; Stefan Faderl; Jorge Cortes; Susan O'Brien; Francis J Giles; Steven M Kornblau; Guillermo Garcia-Manero; Michael J Keating; Michael Andreeff; Sima Jeha; Miloslav Beran; Srdan Verstovsek; Sherry Pierce; Laurie Letvak; August Salvado; Richard Champlin; Moshe Talpaz; Hagop Kantarjian
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

10.  Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.

Authors:  Juan Luis Steegmann; Gemma Moreno; Concepción Aláez; Santiago Osorio; Asunción Granda; Rafael de la Cámara; Eva Arranz; Fernando Gómez Reino; Francisco Rodriguez Salvanés; José María Fernández-Rañada; Cecilia Muñoz
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941
View more
  1 in total

1.  Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial.

Authors:  Xin Xu; Zhiping Fan; Yu Wang; Fen Huang; Yajing Xu; Jing Sun; Na Xu; Lan Deng; Xudong Li; Xinquan Liang; Xiaodan Luo; Pengcheng Shi; Hui Liu; Yan Chen; Sanfang Tu; Xiaojun Huang; Qifa Liu; Li Xuan
Journal:  BMC Med       Date:  2022-09-02       Impact factor: 11.150
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.